| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Director
2 companies
Burroughs Amy L. is a Chief Executive Officer at Terns Pharmaceuticals, Inc. with holdings across 2 companies. Recent SEC Form 4 filings include 4 buys and 3 sells.
Estimated insider holdings value: $17.2M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 15, 2026 | TERN Terns Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE | 68,749 | $37.07 | $2,548,602.83 | -10.5% | +42.3% | - | |
| Jan 5, 2026 | TERN Terns Pharmaceuticals, Inc. | Chief Executive Officer | Sale+OE | 71,339 | $38.10 | $2,718,229.92 | -33.9% | +34.7% | - | |
| Jun 25, 2025 | TERN Terns Pharmaceuticals, Inc. | Chief Executive Officer | Buy | 23,314 | $3.87 | $90,229.84 | +98.1% | +85.0% | - | |
| Dec 5, 2024 | TERN Terns Pharmaceuticals, Inc. | Chief Executive Officer | Buy | 15,450 | $7.15 | $110,467.50 | +423.4% | -43.6% | +355.9% | |
| Nov 30, 2024 | TERN Terns Pharmaceuticals, Inc. | Chief Executive Officer | Buy | 510 | $5.11 | $2,606.10 | +2.7% | -40.9% | +341.2% | |
| Aug 16, 2021 | DMAC Diamedica Therapeutics Inc. | Director | Buy | 44,950 | $3.15 | $141,592.50 | New | +22.5% | -44.1% |